infectious disease, disease & medicine, microbiology

A preprint indicates that coronavirus transmission from surfaces is possible, but does not provide evidence that this has occurred in the COVID-19 pandemic.

Manufacturing sites are ramping up production of reagents needed to isolate SARS-CoV-2’s genetic material—a key step in testing for the virus.

It takes a median of five days after infection to get sick, and patients shed the most coronavirus particles early in the illness, according to two new reports.

The pathogen appears to have come from wild animals, virologists say, and there are no signs of genetic manipulation in the SARS-CoV-2 genome.

Administration officials have given contradictory statements about how COVID-19 will affect the US, and it is not clear who is leading the infectious disease response effort, critics say.

Random mutations in the SARS-CoV-2 pathogen’s genome help researchers track the spread and transmission of COVID-19, the disease it causes.

Saliva tests screen staff and students at University of Illinois; Study ranks species most susceptible to SARS-CoV-2 infection; COVID-19 clinical trials test drugs that inhibit kinin system

Some US states are waiting for the CDC to send replacement enzymes necessary for carrying out SARS-CoV-2 assays.

Researchers find 380 amino acid substitutions between 2019-nCoV and severe acute respiratory syndrome (SARS)-related coronaviruses.

Authorities had silenced Li Wenliang after he spoke out about the virus, now known as 2019-nCoV, in the early days of the epidemic.

Claims that a woman spread the virus to a colleague in Germany before she had symptoms conflict with health officials’ interview with the patient herself.

What is a publication to do when readers misuse its content?

Researchers are trying to figure out where it came from, whether it’s evolving, and just how big a threat it will be.

Scientists release a draft genome of the virus that has been identified in 41 patients.

The virus, which has sickened at least 59 people, does not appear to transmit easily between humans.

Health officials are rushing a genetically engineered product into the field to counter uncontained outbreaks of vaccine-derived polio.

Roughly a quarter of 38 viral samples from people treated with Xofluza had mutations in their genomes that made the pathogens less susceptible to the drug.

Metabolic disrupters, phages, and other approaches are going to be needed to treat the broadest possible range of patients infected by bacterial pathogens resistant to multiple drugs.

Researchers aim to deploy the trial in neighboring Democratic Republic of Congo, which has been ravaged by Ebola for a year.